Iris Acquisition Corp News

10-Q: Quarterly report

SEC announcementMay 23 13:52 ET · Announcements

Iris Acquisition on Pace for Largest Percent Decrease Since June 2021 -- Data Talk

Iris Acquisition Corp Class A (IRAA) is currently at $10.05, down $0.33 or 3.18% --Would be lowest close since Jan. 4, 2023, when it closed at $10.05 --On pace for largest percent decrease since Jun

Dow JonesFeb 27, 2023 11:33 ET

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today's session. LanzaTech Global, Inc. (NASDAQ:LNZA) jumped 27.7% to $5

Benzinga Real-time NewsFeb 21, 2023 10:41 ET

Program CD47, Provided the CMC Service by GenScript ProBio to InnobationBio, Will Further Be Advanced by the Joint Venture Between Liminatus Pharma LLC and Iris Acquisition Corp

PRNewswireDec 5, 2022 07:05 ET

Iris Acquisition, Liminatus Pharma Sign SPAC Merger Deal

04:18 AM EST, 12/01/2022 (MT Newswires) -- Iris Acquisition Corp. (IRAA), a blank-check firm, and clinical-stage biopharmaceutical company Liminatus Pharma said late Wednesday that they have reached a

MT NewswiresDec 1, 2022 04:20 ET

Express News | Liminatus Transaction Is Expected to Close in 1H 2023 >IRAA

Moomoo 24/7Nov 30, 2022 21:00 ET

Combined Company Is Expected to Be Listed on Nasdaq Capital Market, Renamed Liminatus Pharma Inc >IRAA

Combined Company Is Expected to Be Listed on Nasdaq Capital Market, Renamed Liminatus Pharma Inc >IRAA

Dow JonesNov 30, 2022 20:59 ET

Transaction Values Combined Companies at Pro Forma Enterprise Value of $334M >IRAA

Transaction Values Combined Companies at Pro Forma Enterprise Value of $334M >IRAA

Dow JonesNov 30, 2022 20:58 ET

Liminatus Pharma, Iris Acquisition Corp. to Combine, Plan to Operate Under Liminatus Pharma >IRAA

Liminatus Pharma, Iris Acquisition Corp. to Combine, Plan to Operate Under Liminatus Pharma >IRAA

Dow JonesNov 30, 2022 20:57 ET

Press Release: Liminatus Pharma LLC and Iris Acquisition Corp to Combine to Incorporate and Accelerate Much-needed Cancer Treatments

Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments Businesses announce Definitive Business Combination Agreement and plan to operate

Dow JonesNov 30, 2022 20:46 ET

With 57% Ownership, Iris Acquisition Corp (NASDAQ:IRAA) Boasts of Strong Institutional Backing

Yahoo FinanceNov 16, 2022 08:00 ET